EDGAR·FLOW

ROCKET PHARMACEUTICALS, INC. — Form 8-K

Filed October 6, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 71/100
What the filing says
Rocket Pharmaceuticals entered into a Loan and Security Agreement dated September 30, 2026, with Hercules Capital, Inc. as agent and lender, for up to $150,000,000 in aggregate Term Loan Advances across five tranches. The facility is secured by substantially all company assets and is structured to support development of RP-A501 for Danon Disease, with tranche availability contingent on regulatory milestones including an FDA approval milestone for a Biologics License Application.
Why this rating

At $150M against $212.5M market cap, this represents ~71% of company value—transformational liquidity for a clinical-stage biotech. Materially extends runway and de-risks near-term operations, but carries substantial obligations and restrictive covenants.

Tradability signal
NO TRADE

No trade: positive news with only -2.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.03% over 4 hrs, n=201). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.51 ▲ 2.95%
at our read · unknown
$2.44
+10 min · unknown
$2.47 ▲ 1.23%
+30 min · unknown
$2.52 ▲ 3.28%
+1 hr · unknown
$2.57 ▲ 5.33%
+4 hrs · unknown
$2.56 ▲ 5.12%

The stock had already moved -2.87% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ RCKT · stock on Yahoo Finance ↗

See more from October 6, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.